Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Vyndaqel Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The vyndaqel market has experienced swift expansion in recent times. Its value is projected to rise from $1.9 billion in 2025 to $2.23 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.4%. This historical growth has been driven by factors such as the approval of tafamidis, the absence of effective treatments for attr-cm, advancements in cardiac imaging diagnostics, the expansion of rare disease initiatives, and a growing number of cardiology referrals.
The Vyndaqel market is anticipated to experience significant growth over the coming years, reaching a valuation of $4.19 billion by 2030, driven by a compound annual growth rate (CAGR) of 17.1%. This upward trajectory in the forecast period is primarily fueled by factors such as an expanding elderly population, greater awareness of amyloid cardiomyopathy, the proliferation of specialized cardiology centers, broader implementation of genetic testing, and enhanced reimbursement policies. Key developments shaping this period include a rising preference for transthyretin stabilizers, more frequent diagnoses of ATTR cardiomyopathy, the introduction of additional oral treatments for rare cardiac conditions, an intensified focus on disease-modifying cardiac drugs, and the growing application of long-term therapies for amyloidosis.
Download A Free Sample Report For Comprehensive Market Insights:
Vyndaqel Market Expansion Drivers: What Is Shaping Future Growth?
The increasing use of precision medicine is expected to drive the Vyndaqel market forward. This approach tailors medical treatment to individual patients by considering their genetic, environmental, and lifestyle factors, thereby enhancing treatment effectiveness and outcomes. Precision medicine is becoming more widespread as both patients and healthcare providers favor personalized therapies that offer targeted treatment and improved management of chronic conditions. Vyndaqel supports precision medicine by providing a specific treatment for transthyretin amyloidosis (ATTR), ensuring that therapy is directed to those who are most likely to benefit. For example, according to the Personalized Medicine Coalition, a non-profit organization based in the United States, the FDA approved 16 new personalized therapies for rare diseases in 2023—up from six in 2022—as reported in February 2024. As a result, the growing adoption of precision medicine is fueling the expansion of the Vyndaqel market.
The Vyndaqel market is anticipated to grow due to the ongoing increase in healthcare expenditure. Healthcare expenditure encompasses the total amount of money spent on medical products and services aimed at maintaining and enhancing population health. This spending is on the rise because an aging population requires more frequent medical attention and long-term healthcare services. Greater healthcare expenditure facilitates broader access to Vyndaqel by supporting the funding of expensive therapies and improving the infrastructure for diagnosis and care, which is essential for managing transthyretin amyloid cardiomyopathy. For instance, data from the UK’s Office for National Statistics, released in April 2025, showed that total healthcare spending climbed by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024. Hence, the growth of the Vyndaqel market is being driven by rising healthcare expenditure.
Vyndaqel Market Segment Analysis And Revenue Opportunities
The vyndaqel market covered in this report is segmented –
1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg)
2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use
2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use
Vyndaqel Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading firms in the vyndaqel market are prioritizing the expansion of their facilities to manufacture active pharmaceutical ingredients, including transthyretin stabilizing therapeutics designed to improve cardiovascular outcomes and lower hospitalization rates among patients with ATTR-CM. A transthyretin stabilizing therapeutic is a pharmacological compound that attaches to and stabilizes TTR tetramers, thereby inhibiting their breakdown into misfolded monomers which aggregate to form amyloid deposits. As an illustration, in November 2024, BridgeBio Pharma, a biopharmaceutical company based in the United States specializing in genetic disorders, launched Attruby (acoramidis), a transthyretin (TTR) stabilizer achieving near-complete (=90%) activity. This stabilizer is formulated to tackle major issues in transthyretin amyloid cardiomyopathy (ATTR-CM) by binding to TTR tetramers and keeping them stable, thus preventing their dissociation into misfolded monomers that contribute to amyloid buildup in cardiac tissues. The treatment provides notable cardiovascular advantages, such as decreased cardiovascular mortality and fewer hospitalizations related to heart conditions, all while maintaining TTR’s natural physiological roles. Consequently, it serves as an efficient therapy for enhancing patient outcomes and managing ATTR-CM progression.
Vyndaqel Market Leading Players Shaping Industry Direction
Major companies operating in the vyndaqel market are Pfizer Inc.
Access The Complete Vyndaqel Market Report:
Vyndaqel Market Regional Analysis And Leading Geography
North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model